Renal cell carcinoma in a patient with rheumatoid arthritis treated with adalimumab

Current Drug Safety

Volumn 9, Issue 1, 2014, Pages 69-72

  Kobak, Senol ^a   Karaarslan, Ahmet ^a   Aktakka, Yunus ^a  

^a SIFA UNIVERSITY   (Turkey)

Author keywords

Adalimumab; Renal cell carcinoma; Rheumatoid arthritis

Indexed keywords

ACUTE PHASE PROTEIN; ADALIMUMAB; CREATININE; HYDROXYCHLOROQUINE SULFATE; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ABDOMINAL ULTRASONOGRAPHY; ADULT; ANKLE; ARTHRALGIA; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; ECHOGRAPHY; ERYTHROCYTE COUNT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GENERAL SURGERY; HEMATURIA; HUMAN; JOINT SWELLING; KIDNEY CARCINOMA; LOW DRUG DOSE; METACARPOPHALANGEAL JOINT; MIDDLE AGED; MORNING STIFFNESS; NEPHRECTOMY; PRIORITY JOURNAL; PROXIMAL INTERPHALANGEAL JOINT; REMISSION; RHEUMATOID ARTHRITIS; SYNOVITIS; WRIST PAIN;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOPSY; CARCINOMA, RENAL CELL; FEMALE; HEMATURIA; HUMANS; HYDROXYCHLOROQUINE; KIDNEY NEOPLASMS; MIDDLE AGED; NEPHRECTOMY; POSITRON-EMISSION TOMOGRAPHY; PREDNISOLONE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84895454632     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/15748863113086660063     Document Type: Article

References (16)

1. Wolfe F. The natural history of rheumatoid arthritis. J Rheumatol Suppl 1996; 44: 13-22.
2. Young A, Dixey J, Cox N, et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford) 2000; 39(6): 603-11.
3. Pincus T. Rheumatoid arthritis: a medical emergency? Scand J Rheumatol Suppl 1994;100: 21-30.
4. Kuriya B, Arkema E, Bykerk V, Keystone EC. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthiritis: a meta-analysis of clinical and radiographic remission. Ann Rheum Dis 2010; 69(7): 1298-304.
5. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48(8): 2122-7.
6. Baecklund E, Askling J, Rosenquist R, Ekbom A, Klareskog L. Rheumatoid arthritis and malignant lymphomas. Curr Opin Rheumatol 2004; 16: 254-261.
7. Stone JH, Holbrook JT, Marriott MA, et al. Wegener's Granulomatosis Etanercept Trial Research Group. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 2006; 54(5): 1608-18.
8. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295(19): 2275-85.
9. Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials Ann Rheum Dis 2009; 68(7): 1177-83.
10. Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011; 20(2): 119-30.
11. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007; 56(9): 2886-95.
12. The use of the WHO-UMC system for standardised case causality assessment. [last accessed on 2013 Oct 23]; Accessed from: http://www.WHO-UMC.org/graphics/4409.pdf
13. Harrison ML, Obermueller E, Maisey NR, et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 2007; 25(29): 4542-9.
14. Larkin JM, Ferguson TR, Pickering LM, et al. A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. Br J Cancer 2010; 103(8): 1149-53.
15. Balkwill F. TNF-alpha in promotion and progression of cancer Cancer Metastasis Rev 2006; 25(3): 409-16.
16. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104(4): 487-501.